Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma.
- Resource Type
- Case Study
- Authors
- Hashimoto, Rei; Tanabe, Etsuko; Otsuka, Yoshihisa; Yoneda, Yukihiro; Kageyama, Yasufumi
- Source
- Case Reports in Neurology. Sep-Dec2021, Vol. 13 Issue 3, p724-728. 5p.
- Subject
- *IMMUNE checkpoint inhibitors
*ENCEPHALITIS
*MESOTHELIOMA
*IPILIMUMAB
*ANTIBODY titer
*NIVOLUMAB
- Language
- ISSN
- 1662-680X
Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy. [ABSTRACT FROM AUTHOR]